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Background: The aim was to evaluate the metabolic profile in conjunction with vascular function using the
ambulatory arterial stiffness index (AASI) in women with uncomplicated pregnancies and in women with
gestational diabetes mellitus (GDM).
Methods: Plasma glucose, lipids, HOMA –IR (homeostasis model assessment of insulin resistance) and AASI, as
obtained from 24-hour ambulatory blood pressure monitoring in third trimester pregnancy and at three months
postpartum, were measured in three groups of women: controls (N = 32), women with GDM on diet (N = 42) and
women with GDM requiring insulin treatment (N = 10).
Results: Women with GDM had poorer glycemic control and higher HOMA-IR during and after pregnancy and
their total and LDL (low density lipoprotein) cholesterol levels were significantly higher after pregnancy than in the
controls. After delivery, there was an improvement in AASI from 0.26 ± 0.10 to 0.17 ± 0.09 (P = 0.002) in women
with GDM on diet, but not in women with GDM receiving insulin whose AASI tended to worsen after delivery from
0.30 ± 0.23 to 0.33 ± 0.09 (NS), then being significantly higher than in the other groups (P = 0.001-0.047).
Conclusions: Women with GDM had more unfavorable lipid profile and higher blood glucose values at three
months after delivery, the metabolic profile being worst in women requiring insulin. Interestingly, the metabolic
disturbances at three months postpartum were accompanied by a tendency towards arterial stiffness to increase in
women requiring insulin.Background
Gestational diabetes mellitus (GDM) is defined as glu-
cose intolerance with its onset or first recognition during
pregnancy and it occurs in 3–6% of all pregnancies [1].
In Finland, the frequency is even higher, up to 8% [2].
Individuals with GDM exhibit a tendency to develop dia-
betes in later life [3,4], and it also exhibits an association
with pregnancy-induced hypertension [5]. The metabolic
syndrome with dyslipidemia as one of its components is
more common in women with previous GDM [6,7].
During a GDM pregnancy, the maternal lipids are strong
predictors for fetal lipids and abnormal growth [8], with
high maternal triglyceride levels leading to fetal macro-
somia. When dietary therapy is not successful in main-
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distribution, and reproduction in any mediummedication is required, traditionally this has been insu-
lin. Usually insulin therapy can be discontinued after de-
livery. The vascular changes in GDM have been studied
in many different ways, mainly at the endothelial level
[9]. Paradisi et al. used FMD (flow mediated dilation) to
reveal that endothelial dysfunction was present in those
pregnancies complicated by GDM [10]. In addition, a
history of GDM has been shown to be a risk for endo-
thelial dysfunction [11,12] and increased wall stiffness in
the common carotid artery [13], even after the glucose
tolerance has normalized.
In non-pregnant subjects arterial stiffness is a strong
predictor of risk of suffering cardiovascular events. Many
techniques have been used for measuring large artery
stiffness, each with their own strengths and limitations
[14]. The ambulatory arterial stiffness index (AASI) is a
novel index, which is defined as 1 minus the regression
slope of the diastolic and systolic blood pressure values
in individual subjects being determined from non-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[15]. AASI has been shown to correlate with more clas-
sic techniques such as pulse wave velocity and augmen-
tation index and it is claimed to be able to detect arterial
dysfunction at a younger age than can be achieved with
pulse pressure [16]. The normal values of AASI have
been proposed to be <0.50 at 20 years and <0.70 at 80
years [15,16]. AASI has been shown to predict cardio-
vascular deaths and strokes more precisely than classical
risk factors even in normotensive subjects [15,17] and to
be associated with target organ damage in individuals
with arterial hypertension, i.e. left ventricular hyper-
trophy, carotid artery abnormalities and reduced renal
function. [18,19]. Previously we have studied AASI in
uncomplicated singleton and twin pregnancies [20].
Blood pressure displays a circadian pattern with a
blood pressure reduction (dipping) during the night-
time, and this also occurs during normal pregnancy.
Frequently, a 10% fall has been used as a cutoff for a
normal blood pressure daytime-night-time reduction. In
many previous studies, a reduction in the decline in the
nocturnal blood pressure has been claimed to be a pre-
dictor for cardiovascular risk [21-23] and it also has
been shown to be associated with arterial stiffness [24].
The hypothesis for the present study was that women
with GDM would display changes in lipids and vascular
function both during and after pregnancy. Specifically,
this study set out to determine the changes in lipids and
in vascular function using AASI in the third trimester of
pregnancy and at 3 months postpartum in women with
normal singleton pregnancies and in women affected by
GDM being treated with or without insulin.
Methods
We prospectively studied 84 Caucasian childbearing
women (52 with gestational diabetes mellitus and 32
with an uncomplicated pregnancy as controls) during
the third trimester. A total of 10 women in the GDM
group needed insulin to maintain the target glucose
values but the others achieved adequate glycemic control
through dietary measures. Three months after delivery,
we studied 58 of these women (24 from the diet GDM
group, 7 from the group requiring insulin, and 27 con-
trols). Twenty-six women had to be excluded, because
they did not come to the second visit after delivery.
Women were recruited from the Kuopio University
Hospital maternity clinic, where the control subjects were
referred initially for clinical check-up visits for a variety of
reasons, but after consultation, the course of their preg-
nancy was considered as normal. Women with GDM were
referred to our clinic because they were diagnosed with
this metabolic disturbance. Gestational diabetes was deter-
mined as an abnormal 75 g oral glucose tolerance test
(OGTT) [normal capillary plasma values after 12 h offasting being lower than 4.8-11.2-9.9 mmol/l (fasting
-1h-2h)]. The criteria levels were adopted and modified
from a local study [25]. The OGTT was performed on
pregnancy weeks 26–28. Plasma glucose levels were deter-
mined by the hexokinase method (Konelab 60i Clinical
Chemistry Analyzer, Thermo Electron Co, Finland).
Women with at least one value over the limits were
included into the GDM group. Of the GDM group,
91.7% had fasting glucose higher than the reference
value, 27.7% had the 1-h value and 4.3% had the 2-h
value higher than the reference value.
Women with GDM received structured dietary and ex-
ercise advice and were taught home blood glucose
monitoring by a diabetes specialist nurse. The recom-
mendation was to measure fasting blood glucose in the
morning and postprandial glucose levels 1 h after a meal.
If there were values over the limits (fasting glucose >6.0
mmol/l and postprandial >7.5mmol/l) despite nutritional
advice and exercise, then insulin-therapy was initiated
according to our unit’s protocol. Patients were followed
up in our specialized antenatal diabetic clinic according
to a well-established care protocol.
Ambulatory blood pressure recordings
Twenty-four-hour ambulatory blood pressure measure-
ments were conducted using an ambulatory blood pres-
sure system (SpaceLabs 90207; SpaceLabs Medical, Inc.,
Redmond, Washington, USA.) The cuff was placed in
the nondominant arm at the brachial level. We pro-
grammed the recorders to take blood pressure readings at
15- minute intervals during the daytime and every 30-
minutes during the night-time. The duration of night-time
was defined individually for each participant according to
their normal rhythm. The values obtained from twenty-
four-hour ambulatory blood pressure measurements may
be regarded as reproducible [26]. AASI was calculated as
1 minus the regression slope diastolic blood pressure
values plotted against systolic pressures obtained from in-
dividual twenty-four-hour monitoring [15]. The slope was
not forced through the origin.
The nocturnal blood pressure fall was defined as the
difference between individual daytime and night-time
values of systolic and diastolic pressures, respectively. In
our study, individuals with nocturnal systolic blood pres-
sure less than 10 mmHg lower than their values daytime
were defined as nondippers.
Assays
Overnight fasting blood samples were acquired for
laboratory measurements. Samples were centrifuged at
2000 g for 10 minutes and serum and plasma were sepa-
rated. All lipid analyses were performed by standard meth-
ods with Konelab 60i Clinical Chemistry Analyzer (Thermo
Electron Co, Finland). The triglyceride concentration was
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(Konelab TRIGLYCERIDES kit, Thermo Electron Co,
Finland) and the total serum cholesterol concentration
was analyzed by an enzymatic, photometric assay
(Konelab CHOLESTEROL kit, Thermo Electron Co,
Finland). Concentrations of high density lipoprotein
(HDL)-cholesterol and low-density lipoprotein (LDL)-
cholesterol were determined by a direct, enzymatic,
photometric method (Konelab HDL-CHOLESTEROL and
Konelab LDL-CHOLESTEROL kits, Thermo Electron Co,
Finland). Serum insulin was measured by the electroche-
miluminescence immunoassay method (Cobas 6000
analyzer, Hitachi High Technology Co, Tokyo, Japan). The
homeostasis model assessment of insulin resistance
(HOMA-IR) was used to estimate the levels of insulin
resistance with the equation: HOMA-IR= fasting insulin
(mU/l × fasting glucose (mmol/l)/22.5 [27].
All statistical calculations were performed with the
SPSS for Windows programs (SPSS, Chicago, IL). Statis-
tical significance of difference between the groups were
analysed by the T-test and One-Way ANOVA. A gener-
alized linear model was used and BMI was used as a
covariate. Post hoc analyses were performed, where ap-
propriate. Data are shown as mean ± s.d. A P-value
<0.05 was considered statistically significant.
The study was approved by the Ethics Committee of
the Kuopio University Hospital, and all participants pro-
vided informed consent.
Results
The clinical characteristics of the three study groups are
shown in Table 1. There were no differences in the mean
maternal age, height or pregnancy weight gain betweenTable 1 Clinical characteristics of 84 women
Variable Controls (N = 32)
(mean ± SD)
Age (years) 31.2 ± 4.7
Height (cm) 166.4 ± 6.8
Weight before pregnancy (kg) 63.4 ± 7.8†
Weight at birth (kg) 77.1 ± 9.2†
Weight gain (kg) 12.8 ± 3.2
Weight 3 months after delivery (kg) 63.9 ± 8.3†
Body mass index before pregnancy 22.9 ± 2.9†
Body mass index 3 months after delivery 22.3 ± 2.9†
Gestational age at 1. visit (weeks) 34.1 ± 3.3
Gestational age at birth (weeks) 39.9 ± 0.92
Birth weight (grams) 3597 ± 508
Apgar 1 min 8.78 ± 0.98
Apgar 5 min 9.00 ± 0.62
*= significant difference when compared to the control group, †=significant differe
Comparisons performed using One-Way Anova.the groups. The weights of women (P = <0.001) and
values of BMI (P = <0.001) before pregnancy in the
GDM groups were significantly higher than those of the
control group. The mean birth weight in the GDM
group was not significantly higher than in controls. Dur-
ing pregnancy, there were marked metabolic differences
between GDM and control groups. The mean maternal
weight, glucose and HOMA-IR levels were significantly
higher in both GDM groups than in the controls (P =
0.000- 0.013) (Figure 1A). There were no significant dif-
ferences in serum lipids during pregnancy.
Three months after delivery, there were statistically
significant differences between the control group and
insulin-using GDM group in all serum lipids and glu-
cose; i.e. there were elevated levels of total cholesterol,
LDL, triglycerides and HOMA-IR, whereas the HDL
value was lower in GDM insulin group. In women with
GDM on diet, the levels of fasting glucose, LDL, trigly-
cerides, and HOMA-IR were significantly higher than in
controls (Figure 1B). In the comparison of the situation
of the women during their pregnancy and three months
after delivery, there were marked changes in all serum
lipids (P = 0.000-0.038) in controls and GDM group con-
trolled by diet. In the insulin-receiving GDM group, there
was a significant change only in the HDL (P = 0.006),
which decreased after pregnancy. After adjustment for
BMI, the differences between the groups did not remain
statistically significant in terms of total cholesterol, HDL-
cholesterol and triglycerides measured after pregnancy. In
the control group, the BMI value after delivery was signifi-
cantly lower than before pregnancy (P = 0.027) but in
women with GDM controlled by diet, it tended to be
higher (P = 0.092) (Table 1.).Diet GDM (N = 42) Ins. GDM (N = 10)
30.5 ± 5.6 32.8 ± 7.6
165.3 ± 5.7 165.4 ± 4.5
76.2 ± 16.2* 84.4 ± 21.3*
86.8 ± 12.7* 96.9 ± 16.5*
12.9 ± 5.5 11.5 ± 6.3
78.0 ± 14.8* 81.5 ± 8.3*
27.9 ± 5.5* 30.9 ± 8.3*
28.9 ± 5.4* 29.3 ± 2.7*
33.5 ± 3.1 34.0 ± 2.6
40.0 ± 1.5 39.1 ± 1.5
3793 ± 480 3744 ± 537
8.38 ± 1.82 8.20 ± 1.23
8.95 ± 0.67 8.70 ± 0.95
nce when compared to the GDM groups. Significant difference = p <0.05.
Figure 1 The differences in metabolic variables between the
groups (mean ± standard deviation). A= during pregnancy, B= 3
months after delivery. *= P <0.05, ** =P <0.01, ***=P < 0.001.
Comparisons performed using One-Way ANOVA. The numbers of
subjects in each group correspond to those in Table 2.
Kärkkäinen et al. BMC Pregnancy and Childbirth 2013, 13:9 Page 4 of 8
http://www.biomedcentral.com/1471-2393/13/9In the comparison between the women controlling
GDM by diet and with insulin, there were significant dif-
ferences in fasting glucose levels during pregnancy (P =
0.011) and HOMA-IR:s during and after pregnancy (P =
0.018, P = 0.044, respectively.) In all of the women trea-
ted with insulin, hormone administrations were contin-
ued only until the time of delivery.
The hemodynamic variables of the three study groups
are shown in Table 2. Statistically significant differences
between the groups were found both during and after
pregnancy in both systolic and diastolic blood pressures,
all values being highest in the insulin group, as shown.
After adjustment for BMI, the differences did not remain
statistically significant in postpartum systolic blood pres-
sures. However, AASI after pregnancy was significantlyhigher in the insulin group compared to the other
groups (Figure 2). AASI was unchanged in the control
group during pregnancy and after delivery, but in the
GDM group controlled by diet there was a significant
improvement in AASI i.e. from 0.26 ± 0.10 to 0.17 ±
0.09 (P = 0.002). In the insulin-using group, the change
occurred in the opposite direction, i.e. AASI worsened
after delivery from 0.30 ± 0.23 to 0.33 ± 0.09 (Figure 2).
The change in AASI (Δ AASI) was defined as AASI after
delivery – AASI during pregnancy and the value was
negative (−0.08 ± 0.12) in the GDM diet group but posi-
tive in the controls (0.01 ± 0.15) and in the GDM group
requiring insulin (0.03 ± 0.23). The difference in Δ AASI
was significant only between controls and women with
GDM on diet (P = 0.021).
In all three groups, the heart rates were significantly
higher during pregnancy than three months later
(P ≤0.000).
The factors correlating with AASI during pregnancy
and AASI after delivery are shown in Table 3. AASI dur-
ing pregnancy correlated positively with systolic blood
pressures and night-time blood pressures during preg-
nancy, woman’s age and with body mass index before
pregnancy. A negative correlation was found between
AASI during pregnancy and nocturnal diastolic dipping.
There was no correlation between AASI values and 2-
hour glucose test measurement results. AASI values
measured 3 months after delivery correlated positively
with values of systolic and diastolic blood pressure
during the whole 24 hours, but the most significant as-
sociation was recorded with night-time blood pressures
(P = 0.001-0.003). It also correlated negatively with
nocturnal systolic dipping after delivery and diastolic
dipping during pregnancy.
Discussion
It has been previously shown that up to one third of
women with a history of GDM develop the metabolic
syndrome in a period of approximately ten years [6,7].
The present study reveals that a number of metabolic
risks such an unfavourable lipid profile, HOMA-IR and
higher blood pressure were clustering at three months
postpartum in women with GDM and that in women
with GDM requiring insulin, the unfavourable metabolic
profile was accompanied by significantly higher AASI
than in the control women and in women with GDM
controlled by nutritional therapy. Overall, at least three
interesting conclusions can be drawn from this study.
First, in women with GDM controlled by diet, the subtle
increase in arterial stiffness observed during pregnancy
was found to be totally reversible, although in the post-
partum period they did not adhere to the prudent diet
to which they were committed during pregnancy. This
was reflected by the fact that the lipid profiles during
Table 2 Ambulatory measurements
Controls GDM and diet GDM and insulin
Variable 1.visit 2.visit 1.visit 2.visit 1.visit 2.visit
mean ± SD (N = 32) (N = 27) (N = 42) (N = 25) (N = 10) (N = 6)
Systolic BP office (mmHg 109.1 ± 7.5 103.5 ± 7.8 ♦ 112.7 ± 10.4 111.9 ± 21.8 116.5 ± 15.9* 115.5 ± 12.1*
Diastolic BP office (mmHg) 68.9 ± 6.3 70.1 ± 5.7 70.1 ± 9.0 71.8 ± 8.7 75.0 ± 7.8* 79.8 ± 9.4*
Systolic BP whole 24 h (mmHg) 114.5 ± 7.0 112.0 ± 7.4 115.2 ± 9.0 113.8 ± 10.5 123.1±13.3†* 120.3 ± 6.0*
Diastolic BP whole 24 h (mmHg) 71.0 ± 5.9 71.7 ± 6.3 68.8 ± 7.4 69.8 ± 8.8 74.3 ± 8.4† 77.5 ± 6.6
Heart Rate 24 h (bpm) 81.8 ± 9.1 69.0 ± 8.6 ♦ 85.5 ± 10.6 72.9 ± 9.2♦ 80.6 ± 6.6 75.0 ± 6.8♦
Systolic BP daytime (mmHg) 117.7 ± 7.0 115.2 ± 7.4 119.3 ± 9.4 117.7 ± 10.5 125.8 ± 13.2* 123.8 ± 8.5*
Diastolic BP daytime (mmHg) 74.8 ± 5.7 75.3 ± 5.9 73.2 ± 8.0 73.9 ± 8.5 77.4 ± 8.2 81.0 ± 8.7
Heart rate daytime (bpm) 85.4 ± 9.6 73.5 ± 9.2 ♦ 89.4 ± 11.0 77.2 ± 9.2♦ 94.1 ± 6.9 78.8 ± 7.5♦
Systolic BP night (mmHg) 107.2 ± 8.0 105.7 ± 8.6 106.7 ± 9.3 106.1 ± 11.9 116.7± 15.0†* 115.7 ± 4.4*
Diastolic BP night (mmHg) 62.3 ± 7.2 64.7 ± 7.6 ♦ 59.6 ± 7.3 61.0 ± 10.0 67.0 ± 9.5† 72.3 ± 5.3 †*
Heart rate night (bpm) 73.3 ± 9.0 59.4 ± 9.0 ♦ 76.7 ± 10.5 63.5 ± 9.8♦ 72.9 ± 7.8 67.0 ± 9.4
Nocturnal syst. dipping (mmHg) 10.5 ± 4.3 9.4 ± 5.3 12.6 ± 5.7 11.8 ± 5.8 9.1 ± 5.3 8.2 ± 5.6
Nocturnal diast. dipping (mmHg) 12.6 ± 3.8 10.6 ± 4.2 ♦ 13.6 ± 4.7 12.8 ± 5.0 10.4 ± 5.9 8.7 ± 3.9
AASI 0.22 ± 0.13 0.21 ± 0.13 0.23 ± 0.12 0.17 ± 0.09♦ 0.29 ± 0.21 0.33 ± 0.09 †*
1. visit, during pregnancy, 2. Visit, three months after delivery. BP, blood pressure, AASI, ambulatory arterial stiffness index, bpm, beats per minute. *, significant
difference when compared to the control group, †, significant difference when compared to the GDM diet group, ♦, significant difference when compared to 1.
visit. Significant difference = p <0.05.
Figure 2 Ambulatory arterial stiffness index measured during
the third trimester and three months after pregnancy in each
group. Only women with two AASI results were included.
* = P = 0.047 between the controls and the insulin group,
# = P = 0.001 between the GDM groups (Student t test was used).
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somewhat better in the GDM than in the control group
and accordingly the weight gain during, but not after
pregnancy, was similar in both groups. Second, those
women with GDM receiving insulin appeared to develop
more severe dyslipidemia and exhibited an increasing
trend in arterial stiffness after delivery, indicating that
the metabolic disease in a stepwise manner was accom-
panied by notable changes in a vascular function and
suggesting that there really was a dose and response type
of relationship. Savvidou et al.[28] have shown that preg-
nancies complicated by insulin resistance are associated
with systemic maternal arterial stiffness increasing pro-
gressively from controls to gestational to type 2 diabetics
which our results now confirm. The study of Davenport
et al. [29] indicated that the vascular function of women
in the early postpartum period is directly influenced by
the development of GDM during pregnancy and by the
persistence of clinical and/or subclinical hyperglycemia
after delivery, a phenomenon observed also in our study.
AASI during pregnancy correlated positively with the
mother’s age and the correlation with age and AASI
after delivery was also almost statistically significant.
These findings are in line with the results of previous
studies [16]. Pre-pregnancy BMI correlated also with
AASI during pregnancy. Accordingly, the positive corre-
lations with the night-time blood pressure values and
the observed negative correlation with nocturnal dia-
stolic dipping are phenomena that have been detected
Table 3 Significant correlations between selected variables and AASI during pregnancy and after delivery
AASI During pregnancy (N=84) AASI After delivery (N=58)
Systolic BP whole 24 h during pregnancy r = 0.247* r = 0.212
Systolic BP night-time during pregnancy r = 0.286** r = 0.244
Diastolic BP night-time during pregnancy r = 0.215* r = 0.204
Systolic BP whole 24h 3 months after delivery r = 0.225 r = 0.341*
Diastolic BP whole 24h 3 months after delivery r = 0.032 r = 0.280*
Systolic BP night-time 3 months after delivery r = 0.227 r = 0.410**
Diastolic BP night-time 3 months after delivery r = 0.045 r = 0.395**
BMI before pregnancy r = 0.248* r = 0.078
Woman’s age r = 0.245* r = 0.246
Nocturnal diastolic dipping during pregnancy r = -0.386** r = -0.317*
Nocturnal systolic dipping 3 months after delivery r = -0.077 r = -0.344*
AASI, ambulatory arterial stiffness index, BP, blood pressure, BMI, body mass index. Significant difference =* p < 0.05, ** p = < 0.01.
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present results [30].
A reduction in the decline in the nocturnal blood
pressure is claimed to be a predictor for cardiovascular
risk [21-23] and it also has been shown to be associated
with arterial stiffness [24]. This was also seen within the
groups in the present study, even though the differences
between the groups were not statistically significant.
The mechanisms behind the present results remain
speculative, but they may be related to fundamentally
different metabolism in women with metabolic risks. In
the women with GDM, those with the lowest beta-cell
function will require insulin in pregnancy [31] and the
effect of providing insulin may have had some impact on
the results i.e. insulin is known to possess vasodilatory
properties and it may thus mask the effect of impaired
glucose tolerance [32]. On the other hand, the second
half of pregnancy is known to be characterized by
acquired insulin resistance that improves immediately
after pregnancy. Furthermore, there is also a link be-
tween fat mass, lactation, sex steroids and glucose me-
tabolism. We do not have any data on how many of the
mothers in our study were breast-feeding, but three
months after delivery, the vast majority, up to 78%, of
mothers is known to breast-feed in Finland [33]. Lacta-
tion is an oestrogen-deficient state, predisposing women
to abdominal and visceral fat accumulation. The effect
of oestrogen may be reflected in eating or activity beha-
viours and thus on mechanisms that have a direct effect
also on glucose metabolism. Oestrogen treatment in
mice is known to increase lipolysis in abdominal fat cells
and to modulate leptin responsiveness in several ways.
[34]. Oestrogen deficiency in female animals is also
known to be associated with hyperphagia and increased
body weight, the effects probably being mediated by
neuropeptide Y, agouti-related peptide, proopiomelan-
cortin and ghrelin [34,35]. However, little is knownabout the effects of lactation on vascular function, al-
though the metabolic effects seen in the present study
were clear-cut across the full spectrum of gestational
glucose intolerance.
Impaired glucose tolerance and hypertensive problems
during pregnancy have been considered to be a potential
window into a woman’s future [36] revealing tendencies
about whether she will suffer cardiovascular problems
such as hypertension or diabetes mellitus later in life. In
our study, there was transient stiffening in the arteries
during pregnancy with a restoration of elasticity after de-
livery in the group of GDM women who were being
controlled by nutritional treatment but not in the insulin
requiring group, despite the fact that they adhered to a
strict diet. Using the previously established cut-offs
[15,16], the AASI values were within the normal age-
related limits in both groups and therefore, the clinical
significance of the observed AASI changes will require
further study. Overall, this may have true clinical signifi-
cance, as it is believed that AASI predicts cardiovascular
complications, even in normotensive subjects.
One weakness of our study was the rather small num-
ber of participants and in addition there quite many
dropped out. One obvious reason for the considerable
number of drop-outs was the presence of the newborn
baby, who occupied all the mother’s attention. The opti-
mal time for recording AASI values during pregnancy is
not known. On the other hand, there is evidence that
arterial elastic properties may worsen during the third
trimester in normal pregnancies [37,38], suggesting that
AASI measurements would have been different if they
had been conducted earlier in the pregnancy. In the
current setting, third-trimester pregnant women were
enrolled since pregnancy specific changes, such as
GDM, had become manifested and were being diag-
nosed by that time. Accordingly, the normality of the
controls could not have been verified earlier than near
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the third trimester. Otherwise, the subjects of the
present study were young and were considered to be
healthy before and after their pregnancy. The cut-off
values for GDM diagnostics in OGTT in Finland have
changed since our study, being now 5.3 -10-8.6 mmol/l,
and there is the possibility that the results would have
been changed slightly if the updated cut-off values had
been used.
Conclusions
In conclusion, GDM women adhering to a strict diet or
those receiving insulin therapy, displayed signs of
increased arterial stiffness during GDM pregnancy. The
observed increase in arterial stiffness was more pro-
nounced in those women requiring insulin, as expected
on the basis of the severity of the metabolic disturbance.
In women whose GDM was being controlled by dietary
measures, the increase in arterial stiffness was reversible
whereas in women requiring insulin therapy the
observed increase in arterial stiffness still appeared to be
present three months after delivery. Nevertheless, the
AASI values were within the normal limits in all groups
studied and therefore, as yet there are no clinical impli-
cations. Nonetheless, it is recognized that those pregnant
women who require insulin to maintain the target glu-
cose values are at a true risk of suffering type II diabetes
and experiencing cardiovascular complications later in
life. AASI is a quite novel, simple and inexpensive
method for monitoring arterial stiffness and it may help
to identify women at high risk in a timely manner.
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